John Hood, CEO, Endeavor BioMedicines discusses a potential timeline on availability of ENV-101 for patients with IPF and further validation of the treatment’s safety profile.
Beyond the Ordinary Beyond the Obvious
Beyond the Ordinary Beyond the Obvious
John Hood, CEO, Endeavor BioMedicines discusses a potential timeline on availability of ENV-101 for patients with IPF and further validation of the treatment’s safety profile.
